Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Zepbound (Tirzepatide) Hair Loss: When to Call the Doctor

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Hair loss rate / 5% (5 mg), 4% (10 mg), 5% (15 mg) vs 1% placebo [1]
  • Women vs men / 7.1% vs 0.5% on Zepbound [1]
  • Label explanation / Associated with weight reduction [1]
  • Stopped treatment for hair loss / No Zepbound patient; one placebo patient [1]
  • Where it appears in the label / Adverse reactions table, not warnings and precautions [1]
  • Prompt medical attention in label / Suspected serious hypersensitivity [1]
  • Thyroid symptoms named in label / Neck mass, dysphagia, dyspnea, persistent hoarseness [1]
  • Most-linked hair-loss subtype / Telogen effluvium [2]

What the Zepbound label actually reports

In the two pooled placebo-controlled weight-management trials behind the label (adults with obesity or overweight, with or without type 2 diabetes, up to 72 weeks), hair loss was reported by 5% of patients on 5 mg, 4% on 10 mg and 5% on 15 mg, compared with 1% on placebo [1].

The label also reports hair loss by sex. Hair loss was reported in 7.1% of women on Zepbound versus 0.5% of men, and in 1.3% of women on placebo versus 0% of men [1]. The label says hair loss was associated with weight reduction. It does not establish what caused the hair loss [1]. No Zepbound-treated patient discontinued treatment for hair loss; one placebo-treated patient did [1].

What does the label say about seeking care?

Hair loss appears in the adverse reactions table and is not one of the label's warnings and precautions [1]. The label gives specific care instructions for other reactions:

Suspected serious hypersensitivity. The label says to seek medical attention promptly and discontinue Zepbound [1]. Anaphylaxis and angioedema have been reported with tirzepatide [1].

Thyroid tumor symptoms. The label instructs prescribers to counsel patients about the risk of medullary thyroid carcinoma and to inform them of the symptoms of thyroid tumors: a mass in the neck, dysphagia, dyspnea and persistent hoarseness [1].

Suspected pancreatitis. The label says to watch for persistent or severe abdominal pain, sometimes radiating to the back and sometimes with nausea or vomiting, and to discontinue Zepbound if pancreatitis is suspected [1].

Dehydration risk. The label advises monitoring renal function in patients with reactions that could lead to volume depletion, particularly during dose initiation and escalation [1]. Severe gastrointestinal reactions occurred in 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg versus 1% on placebo [1].

Planned procedures. The label instructs patients to tell healthcare providers about any planned surgery or procedure. Pulmonary aspiration has been reported during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists [1].

What other research says about GLP-1 hair loss

A 2026 systematic review screened 133 studies and included 24 that assessed hair loss with GLP-1 receptor agonists. Semaglutide and tirzepatide showed the highest reported incidence rates and the most frequent signals in pharmacovigilance data; androgenetic alopecia and telogen effluvium were the predominant subtypes; and tirzepatide, which produced the largest weight loss, was most often linked to telogen effluvium. Women were disproportionately affected, and rapid weight loss emerged as a potential contributor [2].

A cross-sectional survey of 254 GLP-1 users in Saudi Arabia (71.3% women, mean age 33.3 years) found no significant difference in how many users reported hair loss by injection type, but severe hair loss was more common among Mounjaro users (43.4%) and Saxenda users (42.9%) than other groups [3]. Mounjaro use was associated with higher odds of reporting hair loss than other injections (adjusted odds ratio 3.02), men were less likely to report it than women (adjusted odds ratio 0.36), and duration of use was not a significant predictor [3]. It is a single-country questionnaire study, so it describes what users reported, not a measured rate.

FDA notes that a report in its adverse event database does not establish that the drug caused the event [4].

Frequently asked questions

When should I call a doctor about hair loss on Zepbound?
The label gives no hair-loss-specific threshold [1]. It calls for prompt medical attention for a suspected serious hypersensitivity reaction, describes thyroid tumor symptoms such as a neck mass, dysphagia, dyspnea or persistent hoarseness, and says to discontinue Zepbound if pancreatitis is suspected [1].
How common is hair loss on Zepbound?
In the pooled weight-management trials, hair loss was reported by 5% of patients on 5 mg, 4% on 10 mg and 5% on 15 mg versus 1% on placebo. By sex, 7.1% of women on Zepbound reported it versus 0.5% of men, and 1.3% of women on placebo versus 0% of men [1].
Did anyone stop Zepbound for hair loss?
No Zepbound-treated patient in the pooled weight-management trials discontinued treatment for hair loss. One placebo-treated patient did [1]. Overall discontinuation for any adverse reaction was 4.8% on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg versus 3.4% on placebo [1].
Is the hair loss from the drug or from the weight loss?
The label says hair loss was associated with weight reduction and was more frequent in women. It does not establish what caused the hair loss [1]. A 2026 systematic review identified telogen effluvium as the subtype most often linked to tirzepatide and named rapid weight loss as a potential contributor [2].
Does hair loss mean my thyroid is affected?
Hair loss is listed among common adverse reactions, separate from the label's thyroid C-cell tumor warning [1]. That warning tells prescribers to inform patients of thyroid tumor symptoms: a mass in the neck, dysphagia, dyspnea and persistent hoarseness [1].
Is hair loss a warning in the Zepbound label?
No. It is in the adverse reactions table, not the warnings and precautions section, which covers thyroid C-cell tumors, severe gastrointestinal reactions, acute kidney injury, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia, diabetic retinopathy, pulmonary aspiration and pen sharing [1].

References

  1. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  2. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2):368504261444578. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
  3. Argobi Y, Jadaan NS, Alshalhoob HB, Alyousef MS, Alotaibi GM, Alwesaibie HS, et al. Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. J Cosmet Dermatol. 2026;25(4):e70835. Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis
  4. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA
Evidence overview for Zepbound (Tirzepatide) Hair Loss: When to Call the Doctor